Sulfur, Selenium Or Tellurium Compound (e.g., Thioalcohols, Mercaptans, Etc.) Patents (Class 514/706)
  • Patent number: 10005879
    Abstract: A method for producing an organic semiconductor device (110) having at least one organic semiconducting material (122) and at least two electrodes (114) adapted to support an electric charge carrier transport through the organic semiconducting material (122) is disclosed. The organic semiconducting material (122) intrinsically has ambipolar semiconducting properties. The method comprises at least one step of generating at least one intermediate layer (120) which at least partially is interposed between the organic semiconducting material (122) and at least one of the electrodes (114) of the organic semiconductor device (110). The intermediate layer (120) comprises at least one thiol compound having the general formula HS—R, wherein R is an organic residue. The thiol compound has an electric dipole moment pointing away from the SH-group of the thiol compound. The electric dipole moment has at least the same magnitude as the electric dipole moment in 4-Phenylthiophenol.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: June 26, 2018
    Assignee: BASF SE
    Inventors: Subramanian Vaidyanathan, Marcel Kastler, Bertha Tan, Mi Zhou
  • Patent number: 9707201
    Abstract: Improvements in or relating to Allium extracts. In particular, improvements in or relating to extending the therapeutic half-life or duration of Allium extracts. The invention further relates to the synthesis of methyl methyl thiosulfinate in a mixture with varying molar or mass ratios depending on the reaction conditions, in particular from either methiin or alliin alone or a mixture of both. Methods of treatment methicillin-resistant Staphylococcus aureus are also provided. Also provided is a kit comprising methiin in a first container and alliin in a second container.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 18, 2017
    Inventors: Norman John Bennett, Edward Dalhousie Ramsey
  • Publication number: 20150147396
    Abstract: Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Parimala Nacharaju, Chaim Tuckman-Vernon, Adam J. Friedman, Pedro Cabrales, Joel M. Friedman
  • Patent number: 9028878
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 12, 2015
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Patent number: 8992960
    Abstract: Briefly described, embodiments of this disclosure, among others, include compositions, gels, methods for synthesizing multifunctional silica based nanoparticle gel, method of treating, preventing, or both treating and preventing, a disease in a plant species, method for simultaneously treating citrus plants for citrus canker and preventing the invasion of an Asian Citrus Psyllid (ACP) vector that carries the pathogen and spreads the citrus greening disease in citrus plants, and the like.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: March 31, 2015
    Inventor: Swadeshmukul Santra
  • Publication number: 20150086651
    Abstract: The present disclosure relates to a skin dressing adapted, on activation, to generate one or more S-nitrosothiols by reaction between a thiol and a nitrite salt in the skin dressing for delivery of nitric oxide to a body site. The skin dressing comprises a source of Cu2+, Zn2+ and/or Fe2+ ions.
    Type: Application
    Filed: October 10, 2014
    Publication date: March 26, 2015
    Inventors: Jan Jezek, Lynne Patricia Watson
  • Patent number: 8962692
    Abstract: The present invention discloses cysteine prodrugs having the general formula: cystine dimers of the cysteine prodrugs having the general formula: protected cysteine analogs having the general formula: and dimers of the protected cysteine analogs having the general formula: The invention further encompasses pharmaceutical compositions containing the disclosed prodrugs, dimers, and analogs, and methods of using such compounds for treatment of schizophrenia and drug addiction.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: February 24, 2015
    Assignees: Marquette University, UWM Research Foundation, Inc.
    Inventors: James M. Cook, David A. Baker, Wenyuan Yin, Edward Merle Johnson, II
  • Publication number: 20140364387
    Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
    Type: Application
    Filed: June 30, 2014
    Publication date: December 11, 2014
    Inventors: William A. GODDARD, III, Mark MENNA, Stephan PANDOL, Ravinder ABROL
  • Patent number: 8859819
    Abstract: The present invention relates to a compound of the general formula (I) where: X?S, SO or SO2; and one of the radicals R1 and R2 is a hydrogen atom and the other is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); or a COR3 or CONHR3, but not simultaneously, where R3 is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); an aralkenyl, optionally substituted by one or more C1 to C6 alkoxy groups and/or one or more OH group(s); or an aryl radical, optionally substituted by one or more C1 to C6 alkoxy group(s).
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: October 14, 2014
    Assignee: Pierre Fabre Dermo-Cosmetique
    Inventor: Stéphane Poigny
  • Publication number: 20140274683
    Abstract: Compositions including (a) a pollinating insect repelling, controlling, or directing compound or composition and (b) a compound or composition capable of protecting seeds, plant parts, or plants against insect and/or nematode infestation are provided. The disclosure also provides for methods of repelling, controlling, or directing a pollinating insect, for example a bee, while protecting seeds, plant parts, and/or plants against insect and/or nematode infestation. Seeds, plants, and plant parts treated with compositions described herein are also provided for by the disclosure.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 18, 2014
    Applicant: Bayer CropScience LP
    Inventors: Tai-Teh WU, Dick ROGERS, Jian ZHANG, Robert CROFT, Chi Yu Roy CHEN
  • Patent number: 8822535
    Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: September 2, 2014
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
  • Publication number: 20140243385
    Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract. Also disclosed are novel mercaptan compounds, particularly those including a photolabile protecting group, as well as methods of using the compounds for the prevention and treatment of ocular damage and disease.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 28, 2014
    Applicant: Encore Health, LLC
    Inventors: William GARNER, Margaret Garner, Ronald D. Blum
  • Publication number: 20140227272
    Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
    Type: Application
    Filed: February 8, 2014
    Publication date: August 14, 2014
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
  • Patent number: 8796234
    Abstract: In a process for forming a hydrogel, a precursor crosslinkable through disulfide bonds for forming the hydrogel is provided in a solution. The precursor comprises a branched molecular structure, which comprises a plurality of branches. At least three of the branches each comprises a disulfide bond. The pH in the solution is adjusted to initiate thiol-disulfide exchange in the precursor, thus crosslinking the precursor through disulfide bonds formed by thiol-disulfide exchange. After the precursor is sufficiently crosslinked to form a hydrogel, the pH in the solution is adjusted to inhibit further thiol-disulfide exchange in the hydrogel. Further, a hydrogel matrix may comprise a polymer substantially crosslinked through disulfide bonds. The polymer may comprise a hydrophobic poly(amido amine) core and an amino-functionalized hydrophilic shell.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: August 5, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Decheng Wu, Ye Liu, Chee Leng Lay
  • Patent number: 8784862
    Abstract: The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: July 22, 2014
    Assignee: Hemoteq AG
    Inventors: Roland Horres, Marita Katharina Linssen, Michael Hoffmann, Erika Hoffmann, Donate DiBiase, Volker Faust
  • Patent number: 8772274
    Abstract: Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R—R1, where R is phenyl, where R1 is (CH2)n—Se—C(?NH)—NH2, where R2 is (CH2)n—Se—C(?NH)—NH2 or R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: July 8, 2014
    Assignee: The Penn State Research Foundation
    Inventors: Gavin P. Robertson, Subbarao V. Madhunapantula, Shantu Amin, Dhimant Desai
  • Patent number: 8765719
    Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: July 1, 2014
    Assignee: Kagoshima University
    Inventors: Masanori Baba, Yuichi Hashimoto
  • Patent number: 8759558
    Abstract: The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: June 24, 2014
    Assignee: Pronova Biopharma Norge AS
    Inventors: Anne Kristin Holmeide, Ragnar Hovland, Morten Brændvang
  • Patent number: 8758822
    Abstract: The present invention relates to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, and more particularly, to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, including a first step of dissolving a biodegradable polymer in a non-volatile polar organic solvent, a second step of adding poorly soluble drugs to water and the biodegradable polymer solution to produce a dispersion, and a third step of adding the dispersion to emulsifier solutions in a batch under the condition of low mechanical energy level stirring.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: June 24, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Bong Hyun Chung, Yong Taik Lim, Jung Hyun Han
  • Patent number: 8741966
    Abstract: The present disclosure relates to lipid compounds of formula (I): wherein: R1 is chosen from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and are chosen from hydrogen and a C1-C6 alkyl; X is chosen from O, S, SO, SO2, Si, and Se; n=1 or 3; and P1 is chosen from hydrogen; a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P2, P3, and P4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P5 is chosen from hydrogen and a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: June 3, 2014
    Assignee: Pronova Biopharma Norge AS
    Inventor: Anne Kristin Holmeide
  • Publication number: 20140141098
    Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
    Type: Application
    Filed: August 26, 2013
    Publication date: May 22, 2014
    Applicant: Pulmonox Technologies Corporation
    Inventors: Bruce R. Murray, Christopher C. Miller, Douglas R. Hole
  • Publication number: 20140135359
    Abstract: The present invention provides a computer-assisted method of generating a protonophore requiring the use of a computer including a processor. The method includes: designing the protonophore, calculating, using the processor, an estimated protonophoric activity; producing the protonophore if the estimated protonophoric activity corresponds to an U50 of about 20 ?M or less; and determining the uncoupling activity of the protonophore. The present invention also provides novel protonophores that meet the above requirement and their methods of use.
    Type: Application
    Filed: November 12, 2012
    Publication date: May 15, 2014
    Inventor: Louis C. Martineau
  • Patent number: 8703753
    Abstract: Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma an/or actinic keratosis is also provided.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: April 22, 2014
    Assignee: Biomas Ltd.
    Inventors: Benjamin Sredni, Michael Albeck
  • Publication number: 20140079630
    Abstract: The invention provides compositions and methods for visualizing particular tissues and delivering one or more therapeutics to that tissue using single-walled carbon nanotubes (SWNTs), which are taken up and delivered to target tissues by specific monocytes in the body. The delivery of SWNT to target tissues allows the visualization of the affected tissue for diagnostics and therapy in diseases where the specific monocyte is implicated in the disease pathogenesis. These nanotubes can be conjugated to a peptide, such as RGD, which helps direct the SWNT-containing monocytes to the vascular endothelium.
    Type: Application
    Filed: September 7, 2013
    Publication date: March 20, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Bryan R. Smith, Eliver Ghosn
  • Patent number: 8673979
    Abstract: S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as chemotherapy or radiotherapy, as well as other symptoms of migraines including phonophobia and photophobia.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: March 18, 2014
    Assignee: Meditor Pharmaceuticals Ltd.
    Inventors: Raphael Barkan, Alexander Mirimsky
  • Patent number: 8637578
    Abstract: Methods and reagents for the formation of disulfide bonds, particularly in proteins, peptides and amino acids. The methods and reagents are particularly useful for the controlled glycosylation of proteins, peptides and amino acids. The methods utilize thiosulfonate or selenenylsulfide compounds as reagents or intermediates. Some proteins and peptides comprising selenenyl-sulfide groups also form part of the invention.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: January 28, 2014
    Assignee: Isis Innovation Limited
    Inventors: Benjamin Guy Davis, David Philip Gamblin, Antony John Fairbanks, Philippe Garnier
  • Publication number: 20130334334
    Abstract: A chemical mixture and a system and method using the chemical mixture to reduce damage to the buried lines and discharge components of a subsurface drip irrigation system from rodents that may otherwise chew through these components. The chemical mixture comprises a liquid base, a surfactant, a dye and an odor producing chemical, preferably methyl mercaptan. The chemical is selected so as to produce an odor which is sufficiently intolerable to rodents to negatively disrupt their life cycle, causing rodents to exit to the surface where they are likely to be eaten by predators and to interfere with their eating and mating activities. The system and method of injecting the chemical mixture into the distribution lines of the drip irrigation system so that the mixture flows into the soil with the irrigation water. The methyl mercaptan binds with the soil, creating an odor that disrupts the life cycle of rodents.
    Type: Application
    Filed: June 19, 2012
    Publication date: December 19, 2013
    Inventors: James M. Legari, Richard H. Clevenger
  • Patent number: 8609076
    Abstract: The present invention relates to the use of polyols of formula (I): or a salt thereof, for preventing the hair from breaking. The invention also relates to a cosmetic composition comprising at least one such polyol or a salt thereof, in a cosmetically acceptable medium, and also to a cosmetic hair treatment process using the said composition.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: December 17, 2013
    Assignee: L'Oreal
    Inventors: Frederic Leroy, Michel Philippe, Philippe Barbarat, Christian Blaise
  • Patent number: 8609636
    Abstract: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: December 17, 2013
    Assignee: Allergan, Inc.
    Inventors: Wenkui K. Fang, Liming Wang, Evelyn G. Corpuz, Ken Chow, Wha-Bin Im
  • Patent number: 8580533
    Abstract: The present invention provides methods for enhancing chemical reactions of molecules, e.g., biomolecules, with destructible surfactants. The chemical reactions may involve and/or be associate with analysis, e.g., solubilizing, separating, purifying and/or characterizing the molecules. In one aspect, the anionic surfactants of the present invention may be selectively broken up at relatively low pH. The resulting breakdown products of the surfactants may be removed from the molecule/sample with relative ease. The invention has applicability in a variety of analytical techniques.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: November 12, 2013
    Assignee: Waters Technologies Corporation
    Inventors: Edouard S. P. Bouvier, Bruce J. Compton, John C. Gebler, Martin Gilar, Ying-Qing Yu, Peter Jeng-Jong Lee, Elizabeth K. Brown
  • Patent number: 8546373
    Abstract: Embodiments of the invention relate generally to formulations comprising methylsulfonylmethane (MSM) and one or more therapeutic agents, and uses of such formulations to treat, inhibit and/or sensitize infectious diseases. In several embodiments, such formulations are effective to treat, inhibit and/or sensitize drug-resistant bacterial microorganisms, for example, methicillin-resistant Staphylococcus aureus (MRSA).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 1, 2013
    Assignee: Biogenic Innovations, LLC
    Inventors: Rodney L. Benjamin, Anthony L. Keller, Jeffrey Varelman
  • Patent number: 8491938
    Abstract: This invention relates to compositions comprising zinc and sulforaphane which can be used in the treatment or prevention of cancer. The invention also relates to methods of treating or preventing cancer, including prostate cancer, which comprises the administration of zinc and sulforaphane to a patient in need thereof.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: July 23, 2013
    Assignee: University of Maryland, Baltimore
    Inventor: Pei Feng
  • Patent number: 8455686
    Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 4, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Keizo Koya, Weiwen Ying, Teresa Kowalczyk-Przewloka, Lijun Sun
  • Patent number: 8445026
    Abstract: Novel methods for biological effective, stable amorphous and monoclinic selenium nanoparticles are disclosed. They are prepared by reacting selenium source with a reducing agent or an oxidative agent in an aqueous media at a temperature between 0-100° C. in the presence of selenium binding polymer molecules such as poly/oligopeptide acids or peptone or nucleic acids or poly/oligosaccharide or their mixtures.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: May 21, 2013
    Inventors: Xueyun Gao, Yi Sun
  • Patent number: 8410177
    Abstract: A compound has Formula VIII where, X is —C(O)R, —C(O)OR, —CN, —NO2, —S(O)2R?, —P(O)(OR)2; each R is individually H, alkyl, or alkenyl; R? is alkyl or akenyl; R1 is aryl, alkenyl, arylalkenyl, heterocyclyl, or heteroaryl; and R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are individually H, alkoxy, or hydroxy. In some cases, X is NO2. Pharmaceutical compositions of the compound of Formula VIII with a pharmaceutically acceptable carrier may be prepared. The compounds may be used for inhibition of cyclooxygenase-2.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: April 2, 2013
    Assignee: Indian Institute of Technology Bombay
    Inventors: Irishi N. N. Namboothiri, Narasimham Ayyagari, Deena Jose
  • Patent number: 8389021
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: March 5, 2013
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Patent number: 8377482
    Abstract: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronization preparation. The synchronization preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: February 19, 2013
    Assignee: Warburton Technology Limited
    Inventors: Robert N. Laurie, William A. Smith
  • Patent number: 8361512
    Abstract: Provided are methods and compositions for increasing CD4+ cell count in mammals, preferably by at least 25%, while undergoing treatment for various conditions whose treatment can have detrimental effects on immune system function. Such conditions include, but are not limited to, HIV infection, cancer, and hepatitis. The compositions include alpha lipoic acid; acetyl L-carnitine; N-acetyl-cysteine; zinc; selenium; vitamin C; bioflavinoid complex; vitamin E; optionally one or more antioxidants selected from co-enzyme Q10 and glutathione; and one or more vitamins or minerals selected from beta-carotene, vitamin A, vitamin B1, vitamin B2, vitamin B6, niacinamide, calcium pantothenate, folic acid, vitamin B12, copper, manganese, chromium, and molybdenum.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 29, 2013
    Assignee: K-PAX Vitamins, Inc.
    Inventor: Jon D. Kaiser
  • Patent number: 8338481
    Abstract: Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: December 25, 2012
    Assignees: Ramot at Tel-Aviv University Ltd., Kadmon Corporation, LLC
    Inventors: Yoel Kloog, Liat Goldberg, Victor J. Bauer
  • Publication number: 20120295977
    Abstract: A method for enhancing the overall beneficial immune system response in a host that works in conjunction with the host's natural immune system response to enhance the host's ability to eliminate infectious microbes while simultaneously suppressing the toxicity of the immune system response to the host. Allium related organosulfur compounds are disclosed which have a various antimicrobial immunomodulatory properties that work together with the host's immune system in the prevention and treatment of disease. Prophylactic and therapeutic treatment is provided by administering an allium related organosulfur compound such that a localized thiosulfinate is caused to be non-enzymatically formed in response to localized generation by activated immune system cells of reactive oxygen species such as hydrogen peroxide. Suitable allium related organosulfur compounds may be administered to the host in an efficient manner through the use of S-AllylMercapto-N-AcetylCysteine (SAMNAC) or similar prodrugs.
    Type: Application
    Filed: June 20, 2012
    Publication date: November 22, 2012
    Inventor: David M. Ott
  • Patent number: 8309541
    Abstract: Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R-R1, where R is phenyl, where R1 is (CH2)nSe—C(?NH)—NH2, where R2 is (CH2)nSe—C(?NH)—NH2 or R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: November 13, 2012
    Assignee: The Penn State Research Foundation
    Inventors: Gavin P. Robertson, SubbRao V. Madhunapantula, Shantu Amin, Dhimant Desai
  • Publication number: 20120213861
    Abstract: Rodenticide compositions that include 2-chloropentafluoropropene, and methods of using such rodenticide compositions, are provided. The rodenticide compositions can be used as fumigants in space fumigation applications. In some examples, the rodenticide compositions can be used as drop-in replacements for methyl bromide in existing rodenticide compositions and methods of exterminating rodents using methyl bromide.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 23, 2012
    Applicant: HONEYWELL INTERNATIONAL INC.
    Inventors: Andrew Joseph Poss, Rajiv Ratna Singh, David Nalewajek, Cheryl Cantlon
  • Patent number: 8247596
    Abstract: There is provided a halogen-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein, m represents 0, 1 or 2, n represents 0, 1 or 2, A represents optionally substituted C3-C7 cycloalkyl or optionally substituted C5-C7 cycloalkenyl group, Q represents a C1-C5 haloalkyl group containing at least one fluorine atom, or a fluorine atom, R1 and R3 independently represent optionally substituted C1-C4 chain hydrocarbon, halogen or hydrogen, R2 and R4 independently represent optionally substituted C1-C4 chain hydrocarbon, —C(?G)R5, cyano, halogen or hydrogen, G represents oxygen or sulfur, and R5 represents optionally substituted C1-C4 alkyl, hydroxyl, optionally substituted C1-C4 alkoxy, optionally substituted C3-C6 alkenyloxy, optionally substituted C3-C6 alkynyloxy, amino, optionally substituted C1-C4 alkylamino, optionally substituted di(C1-C4 alkyl)amino, C2-C5 cyclic amino or hydrogen.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: August 21, 2012
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Hiromasa Mitsudera
  • Patent number: 8226986
    Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: July 24, 2012
    Assignee: Ikaria, Inc.
    Inventors: Kevin J. Tomaselli, Paul A. Hill, Thomas L. Deckwerth, Edward A. Wintner, Csaba Szabo
  • Patent number: 8227517
    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: July 24, 2012
    Assignee: Tosk, Incorporated
    Inventors: William A. Garland, Brian D. Frenzel
  • Patent number: 8222299
    Abstract: A method for enhancing the overall beneficial immune system response in a host that works in conjunction with the host's natural immune system response to simultaneously enhance the host's ability to eliminate infectious microbes while suppressing the toxicity of the immune system response to the host. Allium related organosulfur compounds have a variety of antimicrobial and immunomodulatory properties that work together with the host's immune system in the prevention and treatment of disease. Prophylactic and therapeutic treatment is provided by administering an allium related organosulfur compound such that a localized thiosulfinate is caused to be formed in response to localized generation of reactive oxygen species such as hydrogen peroxide by the activated immune system cells. Allium related organosulfur compounds may be administered to the host in an efficient manner through the use of protein-bound S-AllylMercaptoCysteine or similar prodrugs.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: July 17, 2012
    Assignee: Allium Vitalis Incorporated
    Inventor: David M. Ott
  • Patent number: 8217084
    Abstract: Nutraceutical and dietary supplement formulations for delivering bioavailable thiols to a host, comprising certain organosulfur radicals, such as the allyl mercapto radical, bound to larger molecules such as proteins, resulting in the formation in the host's body of various allium-related compounds such as allicin. The formulations are produced by treating an ingestible material comprising a cysteine-containing protein with a thiol, disulfide, mixed disulfide, thiosufinate or mixed thiosulfinate so as to cause thiol residues to become disulfide bonded to cysteines contained in the protein.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: July 10, 2012
    Assignee: Allium Vitalis Incorporated
    Inventor: David M. Ott
  • Patent number: 8193156
    Abstract: Disclosed is a novel synthetic method for isomeric peptides through an appropriate linkage of L-selenomethionine or Se-Methyl-L-selenocysteine with L-glutamic acid. The novel synthetic method produces isomeric peptides of L-selenomethionine or Se-Methyl-L-selenocysteine that exhibit (i) enhanced water solubility; (ii) enhanced rate of dissolution in water; (iii) enhanced bioavailability; (iv) excellent vascular endothelial growth factor promoting activity; (v) excellent anti-5-alpha-reductase activity; (vi) capabilities to prevent/reduce “hair fall” and promote “hair growth”, thereby maintaining a perfect homeostasis for “hair care”. Cosmeceutical and pharmaceutical compositions comprising the isomeric peptides obtained through an appropriate linkage of L-selenomethionine or Se-Methyl-L-selenocysteine with L-glutamic acid are also disclosed. Other dipeptides with several other amino acids and uses thereof are also disclosed.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: June 5, 2012
    Assignee: Sami Labs Ltd
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Rajendran Ramanujam, Renukeshwar H Chandramouli
  • Patent number: 8178122
    Abstract: Materials and methods, for preparation of coatings based on titanium dioxide for osteointegrated biomedical prostheses. The coatings may comprise nanomaterials having antibacterial properties. For example, an endo-osseous implant is provided with a coating comprised of nanocrystalline material comprising nanoparticles of formula (I) (L-Men+)i,??(I) where AOx represents TiO2 or ZrO2; Men+ is a metallic ion having antibacterial activity, with n=1 or 2; L is a bi functional organic molecule which can simultaneously bind to the metal oxide and to the metallic ion Men+, and i is the number of L-Men+ groups bound to one nanoparticle of AOx.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: May 15, 2012
    Assignee: NM Tech Nanomaterials and Microdevices Technology Ltd.
    Inventors: Carlo Alberto Bignozzi, Francesco Carinci, Stefano Caramori, Valeria Dissette
  • Patent number: 8158137
    Abstract: The present invention relates to nanomaterials comprised of metal oxides associated with cationic metals having antibacterial activity. In particular, the present invention relates to nanocrystalline compounds of formula (I): AOx-(L-Men+) i, (I) where AOx represents the metal oxide or metalloid oxide, with x=1 or 2; Me11“1” is a metal ion having antibacterial activity, with n=1 or 2; L is a bifunctional molecule, either organic or organometallic, capable of binding simultaneously with the metal oxide or metalloid oxide and the metal ion Men+; and i represents the number of L-Men+groups bound to a AOx nanoparticle.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: April 17, 2012
    Assignee: NM Tech Nanomaterials and Microdevices Technology Limited
    Inventors: Carlo Alberto Bignozzi, Valeria Dissette, Alfredo Corallini, Giacomo Carra′, Renato Della Valle